Health Care & Life Sciences » Biotechnology | Oxford Immunotec Global PLC

Oxford Immunotec Global PLC | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
76,581.00
50,365.00
83,715.00
59,110.00
90,332.00
192,844
Total Accounts Receivable
4,754.00
6,823.00
7,058.00
13,265.00
16,981.00
13,658
Inventories
5,450.00
6,425.00
7,099.00
7,437.00
10,142.00
7,767
Other Current Assets
2,242.00
2,755.00
3,592.00
2,390.00
3,027.00
2,511
Total Current Assets
89,027.00
66,368.00
101,464.00
82,202.00
120,482.00
216,780
Net Property, Plant & Equipment
2,964.00
4,537.00
6,284.00
7,793.00
9,067.00
7,144
Total Investments and Advances
362.00
192.00
80.00
200.00
200.00
100
Intangible Assets
331.00
2,722.00
2,006.00
31,009.00
11,816.00
2,544
Other Assets
60.00
30.00
18.00
2,808.00
185.00
-
Total Assets
92,744.00
73,849.00
109,852.00
124,012.00
144,236.00
232,120
ST Debt & Current Portion LT Debt
170.00
137.00
79.00
84.00
91.00
Accounts Payable
2,310.00
2,368.00
3,799.00
3,201.00
6,842.00
Other Current Liabilities
8,653.00
9,063.00
11,603.00
15,205.00
15,512.00
Total Current Liabilities
11,133.00
11,568.00
15,481.00
18,490.00
22,445.00
Long-Term Debt
563.00
454.00
386.00
29,601.00
29,904.00
Provision for Risks & Charges
-
1,218.00
1,293.00
2,593.00
-
Deferred Taxes
-
-
-
-
2,486.00
Other Liabilities
296.00
-
-
364.00
4,258.00
Total Liabilities
11,992.00
13,240.00
17,160.00
51,048.00
56,607.00
Common Equity (Total)
80,752.00
60,609.00
92,692.00
72,964.00
87,629.00
Total Shareholders' Equity
80,752.00
60,609.00
92,692.00
72,964.00
87,629.00
Total Equity
80,752.00
60,609.00
92,692.00
72,964.00
87,629.00
Liabilities & Shareholders' Equity
92,744.00
73,849.00
109,852.00
124,012.00
144,236.00

About Oxford Immunotec Global

View Profile
Address
Milton Park
Abingdon Oxfordshire OX14 4RZ
United Kingdom
Employees -
Website http://oxfordimmunotec.com
Updated 07/08/2019
Oxford Immunotec Global Plc operates as a medical diagnostics company, which develops and commercializes proprietary tests for under-served immune-regulated conditions. Its current product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its products include T-SPOT.